Login to Your Account

Clinic Roundup

Friday, August 30, 2013
Arena Pharmaceuticals Inc., of San Diego, filed an 8-K with the SEC amending data released for its Phase Ib study of APD811, an oral prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension, to include reports of a serious adverse event.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription